Macarena I. de la Fuente

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters et al. · Clinical Cancer Research · 2021 · 234 citations · Full text

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations

Priscilla K. Brastianos, Erin Twohy, Elizabeth R. Gerstner et al. · Journal of Clinical Oncology · 2022 · 92 citations · Full text

Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection

Ashish H. Shah, Anil Mahavadi, Long Di et al. · Journal of Neuro-Oncology · 2020 · 60 citations · Full text

Neuro-oncology, Survival Benefit, Surgical Oncology +7

Bilateral radiation therapy followed by methotrexate‐based chemotherapy for primary vitreoretinal lymphoma

Macarena I. de la Fuente, Juan Pablo Alderuccio, Isildinha M. Reis et al. · American Journal of Hematology · 2019 · 59 citations · Full text

Methotrexate‐based Chemotherapy, Primary Vitreoretinal Lymphoma, Surgical Oncology +16

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

Juan Pablo Alderuccio, Wei Zhao, Amrita Desai et al. · American Journal of Hematology · 2019 · 34 citations

Immunodeficiencies, Immunology, Pathology +17